Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...
Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue ...
A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...
A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole ...
Although head-to-head results on tolerability were missing from the company’s data release, Eli Lilly and Co. said its U.S. FDA-approved weight-loss drug Zepbound (tirzepatide) beat the also-cleared ...
Eli Lilly and Co.’s weight-loss drug Zepbound (tirzepatide) made headlines yet again as the Indianapolis-based firm disclosed top-line data from the Surmount-5 phase IIIb study. The open-label, ...
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
In breast cancer, neoadjuvant chemotherapy reduces the tumor before surgery. However, the response to this treatment does not ...
Spur Therapeutics Ltd. has selected SPR-301 as lead development candidate from its gene therapy program for a genetically ...
Methods that may work well for recruiting and retaining white patients for clinical trials may need to be adjusted to ...
Beacon Biosignals Inc. can rest easy now that it has received U.S. FDA authorization of its predetermined change control plan ...
Eterna Therapeutics Inc. has announced plans to evaluate the ability of ERNA-101 to induce and modulate antitumor immunity in ovarian cancer and breast cancer models through a sponsored research ...